Skip to main content
SpringerLink
Log in

Non-Nucleoside Reverse Transcriptase Inhibitors for Treatment of HIV Infection

  • Living reference work entry
  • First Online:
Encyclopedia of AIDS

  • 320 Accesses

Definition

Non-nucleoside or nucleotide reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral drugs that inhibit the reverse transcriptase enzyme and are used in the treatment of the human immunodeficiency virus type 1 (HIV-1) infection.

Introduction

Treatment of HIV is based on blockage of the different stages of the HIV life cycle. Twenty eight drugs classified into six different classes (nucleoside-analog reverse transcriptase inhibitors [NRTIs], non-nucleoside reverse transcriptase inhibitors [NNRTIs], integrase inhibitors, protease inhibitors [PIs], fusion inhibitors, and CCR5 coreceptor antagonists) are currently available for HIV treatment (Pau and George 2014). Initial antiretroviral therapy (ART) consists of a combination of two NRTIs plus either a NNRTI, a PI, or an integrase inhibitor (Panel on Antiretroviral Guidelines for Adults and Adolescents 2015).

NNRTIs affect viral replication by inhibiting the reverse transcriptase (RT) enzyme, responsible for the...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Anderson MS, Gilmartin J, Mitselos A, Laethem T, van Bortel L, Kraft WK, Guo Y, Dockendorf MF, Wagner JA, Butterton J. Effect of ritonavir (RTV) and Tenofovir (TDF) on the pharmacokinetics of MK-1439, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection. Presented at the Interscience Conference on Antimicrobial Agents & Chemotherapy – 53rd Annual. Denver, CO, 2013; H-1462.

    Google Scholar 

  • Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, van Bortel L, Dockendorf MF, Tetteh E, Ancona JK, Liu R, Guo Y, Wagner JA, Butterton JR. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015a;20(4):397–405.

    Google Scholar 

  • Anderson MS, Khalilieh S, Yee KL, Liu R, Rizk ML, Shah V, Hussaini A, Song I, Ross L, Butterton JR, Fan L. A 2-Way Steady State PK Interaction Study of Doravirine (MK-1439) and Dolutegravir. Presented at the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy – 16th Annual. Denver, CO, 2015b; p. 59.

    Google Scholar 

  • Anderson MS, Chung C, Tetteh E, Yee KL, Guo Y, Rasmussen S, Wagner JA, Butterton JR, Fan L. Effect of ketoconazole on the pharmacokinetics of doravirine (MK-1439), a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. Presented at the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy – 16th Annual. Denver, CO, 2015c; p. 58.

    Google Scholar 

  • Baba M, De Clercq E, Tanaka H, et al. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol Pharmacol. 1991;39:805–10.

    CAS  PubMed  Google Scholar 

  • Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714–21.

    Article  CAS  PubMed  Google Scholar 

  • Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229–37.

    Article  CAS  PubMed  Google Scholar 

  • Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60:33–42.

    Article  CAS  PubMed  Google Scholar 

  • Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27:939–50.

    Article  CAS  PubMed  Google Scholar 

  • Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28:989–97.

    Article  CAS  PubMed  Google Scholar 

  • Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445–56.

    Article  PubMed Central  PubMed  Google Scholar 

  • Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163–74.

    Article  CAS  PubMed  Google Scholar 

  • Dejesus E, Mills A, Bhatti L, Conner C, Storfer S. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients. Int J Clin Pract. 2011;65:1240–9.

    Article  CAS  PubMed  Google Scholar 

  • Friedland GH, Pollard R, Griffith B, et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr. 1999;21:281–92.

    Article  CAS  PubMed  Google Scholar 

  • Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arasteh K, Hoffman C, Rugina S, Osiyemi O, Erscoiu S, Dretler R, Harvey C, Xu X, Teppler H. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-infected patients. J Int AIDS Soc. 2014;17 Suppl 3:19532.

    PubMed Central  PubMed  Google Scholar 

  • Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375–84.

    Article  CAS  PubMed  Google Scholar 

  • Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–61.

    Article  CAS  PubMed  Google Scholar 

  • Healthcare ViiV. Dose ranging study of GSK1265744 plus nucleoside reverse transcriptase inhibitors for induction of human immunodeficiency virus-1 (HIV-1) virologic suppression followed by virologic suppression maintenance by GSK1265744 plus rilpivirine. 2012. Available at https://clinicaltrials.gov/ct2/show/NCT01641809. Accessed June 2015.

  • Hsiou Y, Ding J, Das K, Clark ADJ, Hughes SH, Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 a resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure. 1996;4:853–60.

    Article  CAS  PubMed  Google Scholar 

  • Jackson AG, Else LJ, Mesquita PM, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther. 2014;96:314–23.

    Article  CAS  PubMed  Google Scholar 

  • Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 a resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783–90.

    Article  CAS  PubMed  Google Scholar 

  • Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48.

    Article  CAS  PubMed  Google Scholar 

  • Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796–806.

    Article  CAS  PubMed  Google Scholar 

  • Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38.

    Article  CAS  PubMed  Google Scholar 

  • Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238–46.

    Article  CAS  PubMed  Google Scholar 

  • Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161(1):1–10. Available at http://www.ncbi.nlm.nih.gov/pubmed/24979445

  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2015; Available at http://aidsinfo.nih.gov/guidelines. Accessed 21 July 2015.

  • Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014;28:371–402.

    Article  PubMed Central  PubMed  Google Scholar 

  • Pauwels R, Andries K, Debyser Z, et al. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob Agents Chemother. 1994;38:2863–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55–65.

    Article  CAS  PubMed  Google Scholar 

  • Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010;202:717–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–106.

    Article  CAS  PubMed  Google Scholar 

  • Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16:339–48.

    Article  CAS  PubMed  Google Scholar 

  • Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67:487–92.

    Article  CAS  PubMed  Google Scholar 

  • Study Group. Efficacy of 400mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naïve adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2015;383:1474–82.

    Google Scholar 

  • van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–63.

    Article  PubMed  Google Scholar 

  • Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010;24:503–14.

    Article  CAS  PubMed  Google Scholar 

  • Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.

    Article  CAS  PubMed  Google Scholar 

  • Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e118–20.

    Article  PubMed  Google Scholar 

  • World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013; Available at http://www.who.int/hiv/pub/guidelines/arv2013/download. Accessed June 2015.

Download references

Author information

Authors and Affiliations

  1. The Miriam Hospital, Providence, RI, USA

    Francine Touzard Romo & Karen T. Tashima

  2. Department of Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, USA

    Francine Touzard Romo & Karen T. Tashima

Authors
  1. Francine Touzard Romo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen T. Tashima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francine Touzard Romo .

Editor information

Editors and Affiliations

  1. Dept. Cell & Molecular Biology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

    Thomas J. Hope

  2. Office of Graduate and Postdoctoral Studies, University of Miami, Miller School of Medicine, Miami, Florida, USA

    Mario Stevenson

  3. University of California, San Diego Dept. Pathology, La Jolla, California, USA

    Douglas Richman

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this entry

Cite this entry

Touzard Romo, F., Tashima, K.T. (2015). Non-Nucleoside Reverse Transcriptase Inhibitors for Treatment of HIV Infection. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_439-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9610-6_439-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-9610-6

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation